Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Sep;168(9):1817-1825.
doi: 10.1111/jnc.15946. Epub 2023 Aug 27.

Inflammation-stratified augmentation of vortioxetine with celecoxib: Results from a double-blind, randomized, placebo-controlled trial in major depressive disorder

Erhan Kavakbasi  1 , Emma Sampson  2 , Natalie T Mills  2 , Hikaru Hori  3 , Kathrin Schwarte  1 , Christa Hohoff  1 , K Oliver Schubert  2   4 , Scott R Clark  2 , Célia Fourrier  2 , Bernhard T Baune  1   2   5   6
Affiliations
Randomized Controlled Trial

Inflammation-stratified augmentation of vortioxetine with celecoxib: Results from a double-blind, randomized, placebo-controlled trial in major depressive disorder

Erhan Kavakbasi et al. J Neurochem. 2024 Sep.

Abstract

Low-grade inflammation is considered as a pathophysiological mechanism in a subtype of patients with major depressive disorder (MDD). Anti-inflammatory drugs have shown efficacy in treating MDD. However, it remains unclear how to identify suitable patients for anti-inflammatory treatment of depression. This study investigates the predictive value of pre-treatment high-sensitivity C-Reactive Protein (hsCRP) stratification on the outcome of celecoxib augmentation of vortioxetine. The PREDDICT study was conducted as a randomized, double-blind, placebo-controlled 6-week trial on augmentation of vortioxetine with celecoxib between December 2017 and April 2020 at the University of Adelaide (Australia). The present analysis focusses on the question of whether the pre-treatment hsCRP measurement and stratification of patients to depression with inflammation (hsCRP >3 mg/L) or without inflammation (hsCRP ≤3 mg/L) has an impact on the outcome of anti-inflammatory treatment with celecoxib. A total of n = 119 mostly treatment-resistant MDD patients with moderate to severe symptomatology were recruited in the trial. There was no effect of treatment group (celecoxib or placebo), pre-treatment hsCRP strata (with/without inflammation), or interaction between the two terms on treatment outcome. The results of the current analysis do not support the hypothesis that pre-treatment hsCRP level is predictive for response to anti-inflammatory treatment with celecoxib in MDD patients. Further research is needed to identify appropriate biomarkers for the prediction of anti-inflammatory treatment outcome in depression. CLINICAL TRIALS REGISTRATION: Australian New Zealand Clinical Trials Registry (ANZCTR), ACTRN12617000527369p. Registered on 11 April 2017, http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12617000527369p.

Keywords: anti‐inflammatory treatment; celecoxib; major depressive disorder; non‐steroidal anti‐inflammatory drugs; vortioxetine.

PubMed Disclaimer

References

REFERENCES

    1. Abbasi, S.‐H., Hosseini, F., Modabbernia, A., Ashrafi, M., & Akhondzadeh, S. (2012). Effect of celecoxib add‐on treatment on symptoms and serum IL‐6 concentrations in patients with major depressive disorder: Randomized double‐blind placebo‐controlled study. Journal of Affective Disorders, 141(2–3), 308–314. https://doi.org/10.1016/j.jad.2012.03.033
    1. Akhondzadeh, S., Jafari, S., Raisi, F., Nasehi, A. A., Ghoreishi, A., Salehi, B., Mohebbi‐Rasa, S., Raznahan, M., & Kamalipour, A. (2009). Clinical trial of adjunctive celecoxib treatment in patients with major depression: A double blind and placebo controlled trial. Depression and Anxiety, 26(7), 607–611. https://doi.org/10.1002/da.20589
    1. Arteaga‐Henríquez, G., Simon, M. S., Burger, B., Weidinger, E., Wijkhuijs, A., Arolt, V., Birkenhager, T. K., Musil, R., Müller, N., & Drexhage, H. A. (2019). Low‐grade inflammation as a predictor of antidepressant and anti‐inflammatory therapy response in MDD patients: A systematic review of the literature in combination with an analysis of experimental data collected in the EU‐MOODINFLAME consortium. Frontiers in Psychiatry, 10, 458. https://doi.org/10.3389/fpsyt.2019.00458
    1. Bates, D., Mächler, M., Bolker, B., & Walker, S. (2015). Fitting linear mixed‐effects models using lme4. Journal of Statistical Software, 67, 1–48. https://doi.org/10.18637/jss.v067.i01
    1. Baune, B. T., Sampson, E., Louise, J., Hori, H., Schubert, K. O., Clark, S. R., Mills, N. T., & Fourrier, C. (2021). No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6‐week double‐blind placebo controlled randomized trial. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 53, 34–46. https://doi.org/10.1016/j.euroneuro.2021.07.092

Publication types

Grants and funding

LinkOut - more resources